N-MOmentum

Association of B-cell subsets and AQP4 antibody titers with disease activity in NMOSD 2:51
Association of B-cell subsets and AQP4 antibody titers with disease activity in NMOSD
Friedemann Paul • 27 Apr 2023
Inebilizumab in AQP4+ NMOSD patients with history of immunosuppression treatment: N-MOmentum study 1:56
Inebilizumab in AQP4+ NMOSD patients with history of immunosuppression treatment: N-MOmentum study
Friedemann Paul • 27 Apr 2023
sGFAP as a biomarker in NMOSD 3:14
sGFAP as a biomarker in NMOSD
Friedemann Paul • 27 Apr 2023
Unmet needs in the diagnostics and treatment of NMOSD 3:00
Unmet needs in the diagnostics and treatment of NMOSD
Kazuo Fujihara • 28 Oct 2022
Efficacy of inebilizumab in patients with NMOSD with Fc receptor III-A polymorphisms 5:12
Efficacy of inebilizumab in patients with NMOSD with Fc receptor III-A polymorphisms
Bruce Cree • 13 Jun 2022
Consistent efficacy of inebilizumab across newly presenting and previously treated NMOSD cases 1:48
Consistent efficacy of inebilizumab across newly presenting and previously treated NMOSD cases
Bruce Cree • 13 Jun 2022
Key considerations for clinicians treating NMOSD 2:27
Key considerations for clinicians treating NMOSD
Bruce Cree • 13 Jun 2022
Updates on N-MOmentum: inebilizumab versus placebo in patients with NMOSD 2:44
Updates on N-MOmentum: inebilizumab versus placebo in patients with NMOSD
Bruce Cree • 21 Oct 2021
Diagnostic criteria and treatment updates for NMOSD 5:44
Diagnostic criteria and treatment updates for NMOSD
Kazuo Fujihara • 4 Oct 2021
The content of VJNeurology is intended for healthcare professionals